Duke University

Beth Israel Deaconess Medical Center, Inc.

The UAB Research Foundation (the University of Alabama at Birmingham)

Los Alamos National Security, LLC

Albert Einstein College of Medicine

Los Alamos Security, LLC

Norman L Letvin

Barton F Haynes

Hua-Xin Liao

Bette T Korber

Beatrice H Hahn

William M Fischer

James Theiler

Karina Yusim

Simon J Perkins

Carla L Kuiken

Tanmoy Bhattacharya

William R Jacobs, Jr

Mark Cayabyab

Jae-Sung Yu

Avi-Hai Hovav

The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.

Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens

The disclosure relates to nucleic acids mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids are suitable for use in inducing an immune response to HIV-1 in a human.

Human Immunodeficiency Virus type 1 group M consensus and mosaic envelope glycoproteins

The disclosure generally relates to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same.

Nucleic acids encoding mosaic HIV-1 gag proteins

The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine containing nucleic acids encoding HIV-1 gag mosaic proteins, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.

The present invention relates to mosaic HIV-1 group M Gag sequences and to a composition comprising same.

Human immunodeficiency virus type 1 clade M mosaic gag polypeptides

The present invention relates to nucleic acids encoding mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids of the invention are suitable for use in inducing an immune response to HIV-1 in a human.

Nucleic acids encoding mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens

The present invention relates to mosaic clade M HIV-1 Nef polypeptides and to compositions comprising same. The polypeptides of the invention are suitable for use in inducing an immune response to HIV-1 in a human.

Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins

Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided areexpressing an HIV-1 antigen. Further provided are vaccines capable of inducing an immune response in a mammal against HIV-1 and the malarial pathogen. Additionally provided are methods of inducing an immune response in a mammal against HIV-1 and a malarial pathogen. Also provided are methods of inducing an immune response in a mammal against HIV-1. The methods comprise infecting the mammal with any of the above-described mycobacteria.

Mycobacteria expressing HIV-1 and malaria antigens

The present invention relates to mosaic clade M HIV-1 Env polypeptides and to compositions comprising same. The polypeptides of the invention are suitable for use in inducing an immune response to HIV-1 in a human.

Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens

The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to an HLA-based HIV vaccine.

Immunogenic composition

The present invention relates to a method of immunizing a patient against human immunodeficiency virus (HIV) and to an HLA-based immunogenic composition suitable for use in such a method.

Growing community of inventors

Newton, MA, United States of America

Norman L Letvin